ENLEOFEN BIO PTE LTD
Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.The company is developing innovative, safe and highly effective therapeutics that address today's biggest healthcare challenges, enabling customers to access first-in-class antibody therapeutics for the treatment of fibrotic human diseases.
ENLEOFEN BIO PTE LTD
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2017-04-01
Address:
Singapore, Central Region, Singapore
Country:
Singapore
Website Url:
http://www.enleofen.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
ART BioScience
ART BioScience specializes in mRNA therapeutics for the treatment of rare diseases.
Opsonix
Opsonix is a developer of a pathogen-extracting therapy designed to transform the treatment of bloodstream infections and sepsis.
Spinogenix
Spinogenix is a developer of a new class of therapeutics for neurodegenerative and psychiatric diseases.
Current Employees Featured
Founder
Investors List
Goodman Capital
Goodman Capital investment in Series A - Enleofen Bio Pte Ltd
Official Site Inspections
http://www.enleofen.com
- Host name: 239.212.155.104.bc.googleusercontent.com
- IP address: 104.155.212.239
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Enleofen Bio Pte Ltd"
Enleofen Bio Pte Ltd - Crunchbase Company Profile & Funding
Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases.The company is developing innovative, safe and highly effective therapeutics that …See details»
Enleofen Company Profile 2024: Valuation, Funding & Investors
Enleofen General Information Description. Developer of antibody therapeutics designed to assist in the treatment of fibro-inflammatory diseases. The company's technology involves …See details»
Contact - Enleofen
160 Robinson Road, SBF Centre, # 23-02, Singapore 068914. [email protected]See details»
Incorporation of Enleofen
04 April 17 – Enleofen Bio Pte. Ltd. was founded as a spin-out from National Heart Centre Singapore (NHCS), SingHealth and Duke-NUS Medical School with Series A funding.Enleofen …See details»
Boehringer Ingelheim Partners with Enleofen | BI US
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug …See details»
Enleofen Bio Pte Ltd - Funding, Financials, Valuation & Investors
Apr 4, 2017 Enleofen is a developer of bio technology designed for the treatment of fibro-inflammatory diseases. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ...See details»
Enleofen | VentureRadar
Enleofen is a biotechnology company that specializes in the development of first-in-class therapeutics targeting the IL-11 pathway. The firm focuses on transforming the treatment of …See details»
Enleofen Bio Pte Ltd. - Drug pipelines, Patents, Clinical trials
Learn more at About Enleofen Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. ... The …See details»
Duke-NUS - MEDICUS June 2020
Enleofen was developing bio-therapeutics that could be used in treating a variety of common chronic diseases that result in scar formation, called fibrosis, in internal organs such as the lungs, the heart, or the liver. In December 2019, …See details»
Boehringer Ingelheim partners with Enleofen to develop first-in …
Jan 10, 2020 Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery …See details»
Startup Enleofen Highlights Singapore's Homegrown Research
HONG KONG – Singapore startup Enleofen Bio Pte Ltd. has acquired the licensing rights of a breakthrough discovery by the Duke-National University of Singapore (NUS) Medical School …See details»
Breakthrough discovery presents hope for treating fibrotic
A breakthrough discovery in the field of cardiovascular fibrosis research made at Duke-NUS Medical School (Duke-NUS) and National Heart Centre Singapore (NHCS) has been licensed …See details»
Boehringer buys Enleofen IL-11 platform to boost NASH pipeline
Jan 9, 2020 The latest deal sees Boehringer swallow Enleofen’s anti-IL-11 antibody platform, putting it on the hook for up to $1 billion in milestones per product. Boehringer buys Enleofen …See details»
Boehringer Ingelheim Acquires Enleofen's Anti-IL-11 Therapies for...
Jan 14, 2020 “Enleofen is very excited to engage Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D to develop further anti-IL-11 therapies to begin to address the unmet medical …See details»
News - Enleofen
Ingelheim am Rhein, Germany and Singapore – 9 January 2020 – Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced today the acquisition of worldwide exclusive …See details»
YUMAB: universally accessible human antibody innovation - Nature
In April 2017, Cook and Schäfer founded Enleofen Bio Pte. Ltd., a spin-out from NHCS, SingHealth and Duke–NUS Medical School focused on the development of first-in-class …See details»
Boehringer Ingelheim Partners with Enleofen to Develop First-in …
Jan 9, 2020 Singapore-based Enleofen to receive in excess of one billion USD per product in upfront and success-based development and commercialization milestones January 09, 2020 …See details»
Enleofen announces ENx108A as clinical development candidate
Enleofen Bio Pte Ltd (“Enleofen”), a biotechnology company developing first-in-class therapeutics for the treatment of fibro-inflammatory human diseases, today announced ENx108A, a human …See details»
Press Release – 14 Nov 2017 - Enleofen
Cook and Schäfer are co-founders of Enleofen, a biotechnology company based in Singapore, developing first-in-class therapeutics for the treatment of fibrotic human diseases. A protein …See details»